CN109937047A - nNIF和nNIF相关肽以及相关方法 - Google Patents

nNIF和nNIF相关肽以及相关方法 Download PDF

Info

Publication number
CN109937047A
CN109937047A CN201780067221.2A CN201780067221A CN109937047A CN 109937047 A CN109937047 A CN 109937047A CN 201780067221 A CN201780067221 A CN 201780067221A CN 109937047 A CN109937047 A CN 109937047A
Authority
CN
China
Prior art keywords
nrp
nnif
seq
net
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780067221.2A
Other languages
English (en)
Chinese (zh)
Inventor
C·C·约斯特
G·A·齐默曼
A·S·韦里奇
J·希夫曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of CN109937047A publication Critical patent/CN109937047A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201780067221.2A 2016-09-02 2017-09-05 nNIF和nNIF相关肽以及相关方法 Pending CN109937047A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662383243P 2016-09-02 2016-09-02
US62/383,243 2016-09-02
US201762492019P 2017-04-28 2017-04-28
US62/492,019 2017-04-28
PCT/US2017/050072 WO2018045371A2 (en) 2016-09-02 2017-09-05 nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS

Publications (1)

Publication Number Publication Date
CN109937047A true CN109937047A (zh) 2019-06-25

Family

ID=61309026

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780067221.2A Pending CN109937047A (zh) 2016-09-02 2017-09-05 nNIF和nNIF相关肽以及相关方法

Country Status (13)

Country Link
US (1) US10857201B2 (https=)
EP (1) EP3506924A4 (https=)
JP (1) JP2019534247A (https=)
KR (1) KR20190045271A (https=)
CN (1) CN109937047A (https=)
AU (1) AU2017321965A1 (https=)
BR (1) BR112019004299A2 (https=)
CA (1) CA3035770A1 (https=)
MX (1) MX2019002479A (https=)
RU (1) RU2019109049A (https=)
SG (1) SG11201901830UA (https=)
WO (1) WO2018045371A2 (https=)
ZA (1) ZA201901942B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117004744A (zh) * 2022-04-27 2023-11-07 数字碱基(南京)科技有限公司 一种基于血浆微生物dna特征的肺癌预后评估方法及模型

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324801B2 (en) 2016-09-02 2022-05-10 University Of Utah Research Foundation NNIF and nNIF-related peptides and related methods
US20230158108A1 (en) * 2020-05-04 2023-05-25 University Of Utah Research Foundation Immunothrombosis in covid-19 acute respiratory distress syndrome

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160194365A1 (en) * 2013-07-08 2016-07-07 The University Of Utah Research Foundation Methods for treatment of and prophylaxis against inflammatory disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US9308235B2 (en) * 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160194365A1 (en) * 2013-07-08 2016-07-07 The University Of Utah Research Foundation Methods for treatment of and prophylaxis against inflammatory disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COOLS-LARTIGUE J等: "Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis", 《JOURNAL OF CLINICAL INVESTIGATION》 *
SIMPSON RJ等: "Proteomics-driven cancer biomarker discovery: looking to the future", 《CURRENT OPINION IN CHEMICAL BIOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117004744A (zh) * 2022-04-27 2023-11-07 数字碱基(南京)科技有限公司 一种基于血浆微生物dna特征的肺癌预后评估方法及模型
CN117004744B (zh) * 2022-04-27 2024-05-24 数字碱基(南京)科技有限公司 一种基于血浆微生物dna特征的肺癌预后评估方法及模型

Also Published As

Publication number Publication date
JP2019534247A (ja) 2019-11-28
EP3506924A2 (en) 2019-07-10
CA3035770A1 (en) 2018-03-08
RU2019109049A3 (https=) 2020-12-24
US10857201B2 (en) 2020-12-08
EP3506924A4 (en) 2020-05-20
ZA201901942B (en) 2020-10-28
KR20190045271A (ko) 2019-05-02
MX2019002479A (es) 2019-09-19
WO2018045371A2 (en) 2018-03-08
BR112019004299A2 (pt) 2019-05-28
SG11201901830UA (en) 2019-03-28
RU2019109049A (ru) 2020-10-05
US20190201487A1 (en) 2019-07-04
WO2018045371A3 (en) 2018-04-12
AU2017321965A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
US11752203B2 (en) Methods for treatment of and prophylaxis against inflammatory disorders
EP2209485B1 (en) Extracellular histones as biomarkers for prognosis and molecular targets for therapy
US8212007B2 (en) Expression and purification of HIP/PAP and uses therefor
US20130053329A1 (en) Methods of inhibiting apoptosis or inflammation in a mammal by administering an isolated bcl protein
IE910630A1 (en) COMPOSITIONS AND METHODS FOR TREATING INFECTIONS CAUSED BY¹ORGANISMS SENSITIVE TO ß-LACTAM ANTIBIOTICS
US10889619B2 (en) Methods for treating cancer
US10857201B2 (en) NNIF and nNIF-related peptides and related methods
WO2020109864A1 (en) Dpep-1 binding agents and methods of use
US11324801B2 (en) NNIF and nNIF-related peptides and related methods
JPH08504085A (ja) リポ多糖体結合及び抗擬血活性をもつ哺乳動物のカチオン性タンパク質
CN106794218A (zh) 白细胞的细胞外诱捕网形成抑制剂
HK40004861A (zh) Nnif和nnif相关肽以及相关方法
CN104225576B (zh) 人defb1的用途
US20090162379A1 (en) Inhibitors of S. aureus SdrD protein attachment to cells and uses therefor
Merselis Molecular Functionality, Cellular Trafficking, and Clinical Relevance of the Pore-Forming Protein Perforin-2
Johnson Targeted degradation of mitochondrial aspartyl-tRNA synthetase (DARS2) modulates immune responses in experimental pneumonia
mingtong et al. Caspase-14 recognizes and processes IL-1β in epithelial cells to drive anti-bacterial IgG production
US20120172306A1 (en) Use of HASF as a Protective Agent Against Ischemic Tissue Damage

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40004861

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190625

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40004861

Country of ref document: HK